Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2021 07:00 ET | Source: ALX Oncology

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47...
January 05, 2021 07:00 ET | Source: ALX Oncology

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
December 17, 2020 07:00 ET | Source: ALX Oncology

ALX Oncology Added to the NASDAQ Biotechnology Index

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
December 14, 2020 16:05 ET | Source: ALX Oncology

ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
December 09, 2020 22:26 ET | Source: ALX Oncology

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
December 07, 2020 16:08 ET | Source: ALX Oncology

ALX Oncology Announces Proposed Public Offering of Common Stock

BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
December 07, 2020 10:00 ET | Source: ALX Oncology

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

-- ORR of 70.0% Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached -- Significant Improvement in Clinical Response Demonstrated with...
December 07, 2020 07:00 ET | Source: ALX Oncology

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

-- Due to the registration potential of two planned Phase 2 head and neck cancer studies, FDA has requested completion of a standard ongoing non-clinical safety study -- Initiation of planned Phase...
November 24, 2020 07:00 ET | Source: ALX Oncology

ALX Oncology Announces December 2020 Virtual Investor Conference Participation

BURLINGAME, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
November 12, 2020 16:05 ET | Source: ALX Oncology

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...